Detailed Abstract
[BP Oral Presentation 1 - Biliary & Pancreas (Pancreas Disease/Surgery)]
[BP OP 1-S3] Minimally Invasive Pancreatoduodenectomy with Combined Venous Vascular Resection; a Comparative Analysis with Open Approach
Dong Hyun SHIN 1, Yeon Su KIM 1, Mun Seok CHOI 2, Seoung Yoon RHO 2, Seung Soo HONG 1, Sung Hyun KIM 1, Ho Kyoung HWANG 1, Chang Moo KANG 1
1 Division of HBP Surgery, Department of Surgery, Severance Hospital, REPUBLIC OF KOREA, 2 Division of HBP Surgery, Department of Surgery, Yongin Severance Hospital, REPUBLIC OF KOREA
Background : This study aimed to compare the minimally invasive pancreatoduodenectomy with venous vascular resection (MI-PDVR) and open pancreatoduodenectomy with venous vascular resection (O-PDVR) about periampullary cancer.
Methods : Data of 124 patients who underwent PDVR (45 MI-PDVR, 79 O-PDVR) between January 1, 2016, and December 31, 2023, was collected from Severance Hospital, Seoul, Korea.
Results : MI-PDVR is significantly better than O-PDVR in terms of perioperative outcomes (median operation time (452.69 min. vs. 543.91 min, p=0.004), estimated blood loss (410.44 mL vs. 747.59 mL, p<0.01), intraoperative transfusion rate (2 cases vs. 18 cases, p=0.01), and hospital stay (18.16 days vs. 23.91 days, p=0.008)). The complications until the discharge day showed no significant difference between the two groups (CD<3, 84.4% vs. 82.3%, CD>=3, 15.6% vs. 17.7%, P=0.809). In terms of long-term oncological outcomes, there was no statistical difference in overall survival (OS, median 51.55 months [95% CI: 35.95~67.14] vs. median 49.92 months [95% CI: 40.97~58.87], P=0.340) and disease-free survival (DFS, median 35.06 months [95% CI: 21.47~48.65] vs. median 38.77 months [95% CI: 29.80~47.75], P=0.585) between the two groups. Long-term oncological outcomes for subgroup analysis focusing on pancreatic ductal adenocarcinoma also showed no statistical differences in OS (median OS of 40.86 months [95% CI, 34.45-47.27] vs. median OS 48.48 months [95% CI, 38.16-58.59], P=0.270) and DFS (OS, median 24.42 months [95% CI: 17.03-31.85], vs. median 34.35 months [95% CI: 25.44-43.27], P=0.740)
Conclusions : MI-PDVR is considered to be able to provide better perioperative outcomes and similar oncological impact compared to O-PDVR.
Methods : Data of 124 patients who underwent PDVR (45 MI-PDVR, 79 O-PDVR) between January 1, 2016, and December 31, 2023, was collected from Severance Hospital, Seoul, Korea.
Results : MI-PDVR is significantly better than O-PDVR in terms of perioperative outcomes (median operation time (452.69 min. vs. 543.91 min, p=0.004), estimated blood loss (410.44 mL vs. 747.59 mL, p<0.01), intraoperative transfusion rate (2 cases vs. 18 cases, p=0.01), and hospital stay (18.16 days vs. 23.91 days, p=0.008)). The complications until the discharge day showed no significant difference between the two groups (CD<3, 84.4% vs. 82.3%, CD>=3, 15.6% vs. 17.7%, P=0.809). In terms of long-term oncological outcomes, there was no statistical difference in overall survival (OS, median 51.55 months [95% CI: 35.95~67.14] vs. median 49.92 months [95% CI: 40.97~58.87], P=0.340) and disease-free survival (DFS, median 35.06 months [95% CI: 21.47~48.65] vs. median 38.77 months [95% CI: 29.80~47.75], P=0.585) between the two groups. Long-term oncological outcomes for subgroup analysis focusing on pancreatic ductal adenocarcinoma also showed no statistical differences in OS (median OS of 40.86 months [95% CI, 34.45-47.27] vs. median OS 48.48 months [95% CI, 38.16-58.59], P=0.270) and DFS (OS, median 24.42 months [95% CI: 17.03-31.85], vs. median 34.35 months [95% CI: 25.44-43.27], P=0.740)
Conclusions : MI-PDVR is considered to be able to provide better perioperative outcomes and similar oncological impact compared to O-PDVR.
SESSION
BP Oral Presentation 1
Room B 3/21/2024 3:30 PM - 4:30 PM